Human Insulin Market By Application Analysis, Regional Outlook, Competitive Strategies And Forecast 2021 – 2030

In a recent published report, Kenneth Research has updated the market report for Human Insulin Market for 2021 till 2030. Report further now discusses; the various strategies to be adopted or being adopted by the business players across the globe at various levels in the value chain. In the view of the global economic slowdown, we further estimated that China, India, Japan and South Korea to recover fastest amongst all the countries in the Asian market. Germany, France, Italy, Spain to take the worst hit and this hit is expected to be regain 25% by the end of 2021- Positive Growth in the economic demand and supply.

U.S. Market recovers fast; In a release on May 4th 2021, the U.S. Bureau and Economic Analsysis and U.S. Census Bureau mentions the recovery in the U.S. International trade in March 2021. Exports in the country reached $200 billion, up by $12.4  billion in Feb 2021. Following the continuous incremental trend, imports tallied at $274.5 billion, picked up by $16.4 billion in Feb 2021. However, as COVID19 still haunts the economies across the globe, year-over-year (y-o-y) avergae exports in the U.S. declined by $7.0 billion from March 2020 till March 2021 whilest imports increased by $20.7 billion during the same time. This definitely shows how the market is trying to recover back and this will have a direct impact on the Healthcare/ICT/Chemical industries, creating a huge demand for Human Insulin Market products.

Request To Download Sample of This Strategic Report:

According to a report by the World Health Organization (WHO), the total health spending is growing with an annual average rate of 6% in the low- and middle-income nations, and close to 4% in the high-income countries. Further, in the year 2016, the expenditure made on health reached close to 10% of the GDP of the world and crossed a value of USD 7 trillion.

Global Human Insulin Market – Drivers, Restraints, Opportunities, Trends, and Forecasts: 2017–2023
Overview: Insulin is a peptide hormone that helps in controlling the absorption of fat and carbohydrate in the body. The human insulin market is anticipated to grow at a robust CAGR during the forecast period due to a high incidence rate of diabetes, globally.

The growth in the prevalence rate of diabetes, changes in lifestyles, rising number of obese patients, and increasing geriatric population are the major factors driving the market growth. However, the high cost for the development and production of insulin, manufacturing complexities, and stringent regulatory scenario for the approval of derived products are hampering the growth of the market. The development of pipeline insulin products and expiry of key patents are providing an opportunity for the manufacturers of human insulin.

Market Analysis: The “Global Human Insulin market is estimated to witness a CAGR of 10.2% during the forecast period 2017–2023. The human insulin market is analyzed based on three segments – top insulin brands, product types, and regions.

Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (ROW). North America accounts for the largest share of the global human insulin market, followed by Europe, Asia Pacific, and Rest of the World. Nearly half of the market is occupied by North America, with the US being the major contributor to the market growth.

Product Analysis: Based on types, the market is segmented into modern human insulin and traditional human insulin. Modern human insulin includes rapid-acting insulin analogs, premixed analogue insulins, and long-acting insulin. Traditional human insulin includes regular human insulin, NPH human insulin, and pre-mixed insulin. Novo Nordisk holds 45.0% share of the total modern insulin market.

Request To Download Sample of This Strategic Report:

Top Insulin Brands: Lantus is the major insulin drug in the market. Due to the loss of patents, the drug has got competition in the form of biosimilar by name Basaglar from Eli Lilly. After the loss of share for its biosimilar counterpart, the drug lost its value for its follow-up drug Toujeo. Since the launch of Toujeo in April 2015, the company has been switching over as many patients as possible to the newer drug to fill the sales gap caused by the reduced revenue of Lantus.

Key Players: Novo Nordisk, Sanofi A/S, Eli Lilly & Company, and Astra Zeneca PLC are the key players in the market. The other prominent players in the market include Biocon, Julphar, Wockhardt, GSK, Oramed, and SemBioSys Genetics.

Competitive Analysis: Regardless of the size of the total market, it is chiefly dominated by Novo Nordisk, Sanofi, and Eli Lilly. These firms function globally either independently or through subsidiaries and distributors. The insulin products of Novo Nordisk are sold in 111 countries along with 101 countries for Sanofi’s insulin products and 94 countries for Eli Lilly’s insulin products. Especially in higher income countries of Western Europe, nearly 55% of insulin products are sold by these major manufacturers. Moreover, in 2012, they occupied 88.7% of share in the global insulin market.

However, there are many small companies involved in the production and sales of insulin products. Other major companies in the market are Wockhardt, Biocon, Julphar, Oramed, GSK, and SemBioSys Genetics Inc.
Benefits: The report provides complete details about the usage and adoption rate of human insulin in various regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

Request To Download Sample of This Strategic Report:

Table of Contents
1 Industry Outlook 8
1.1 Industry Overview 8
1.2 Total Addressable Market 8
1.3 Industry Trends 10
2 Report Outline 11
2.1 Report Scope 11
2.2 Report Summary 11
2.3 Research Methodology 12
2.4 Report Assumptions 12
3 Market Snapshot 13
3.1 Market Definition – Infoholic Research 13
3.2 Segmented Addressable Market (SAM) 13
3.2.1 Trends of Human Insulin market 14
3.3 Related Markets 15
3.3.1 Oncology (Cancer) Drugs 15
3.3.2 Active pharmaceutical ingredients (APIs) 16
3.3.3 Over the counter drugs (OTC) 16
3.3.4 Diabetes Drugs 17
4 Market Outline 18
4.1 Pipeline products 18
4.2 Market Segmentation 18
4.3 Porter 5(Five) Forces 19
4.4 PEST Analysis 20
5 Market Characteristics 21
5.1 Market Dynamics 22
5.1.1 Drivers 22 Increasing Aging Population 22 Increasing People Suffering with Diabetes 24
5.1.2 Opportunities 24 Increase healthcare spending 24 Patent Expiry for Blockbuster Drugs 25
5.1.3 Restraints 25 Complex regulatory process 25 High cost of insulin 25
5.1.4 DRO – Impact Analysis 27
5.1.5 Key Stakeholders 28
6 Insulin Types: Market Size and Analysis 29
6.1 Overview 29
6.2 Lantus 29
6.3 Humulin 29
6.4 Levemir 30
6.5 Humalog 30
6.6 NovoLog/NovoRapid 30
6.7 Tresiba 31
6.8 Basaglar/ Abasaglar 31
6.9 Toujeo 31
6.10 Apidra 32
Company: Sanofi 32
7 Types: Market Size and Analysis 33
7.1 Overview 33
7.2 Modern Insulin 34
7.2.1 Rapid Acting Insulin Analogs 34
7.2.2 Premixed analogue insulins 34
7.2.3 Long-acting insulin 34
7.3 Traditional Human Insulin 35
7.3.1 Regular Human Insulin 35

About Kenneth Research

Kenneth Research is a reselling agency providing market research solutions in different verticals such as Automotive and Transportation, Chemicals and Materials, Healthcare, Food & Beverage and Consumer Packaged Goods, Semiconductors, Electronics & ICT, Packaging, and Others. Our portfolio includes set of market research insights such as market sizing and market forecasting, market share analysis and key positioning of the players (manufacturers, deals and distributors, etc), understanding the competitive landscape and their business at a ground level and many more. Our research experts deliver the offerings efficiently and effectively within a stipulated time. The market study provided by Kenneth Research helps the Industry veterans/investors to think and to act wisely in their overall strategy formulation

Contact Us

Kenneth Research
Phone: +1 313 462 0609

Leave a Reply